Search





Search





Immunic rises after board hire of MS drug veteran

ReutersMar 31, 2026 10:55 AM

Shares of biotech firm Immunic IMUX.O rise 5% to $1.08 premarket

Co says it appointed Jon Congleton to its board; he helped launch Teva’s multiple sclerosis drug Copaxone in the United States

Congleton has also served as CEO of Mineralys Therapeutics, Impel NeuroPharma and Nivalis Therapeutics,

Adds it is developing vidofludimus calcium, an oral experimental drug for relapsing multiple sclerosis, a form of the disease with recurring flare‑ups

Co says late‑stage study readouts for the drug are expected by the end of 2026

Multiple sclerosis is a disease in which the immune system attacks nerves, leading to problems with movement and vision

Shares fell ~47% in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

Micron Plunges 10%, Earnings Beat Expectations, Stock Price Falls 30% Consecutively, Can AI Memory Chips Still Be Bought?

TradingKey — Micron Technology’s (MU) recent stock price performance has become a microcosm of shifting sentiment within the AI memory sector. Despite reporting robust earnings, the stock has weakened steadily following the announcement, marking a cumulative decline of nearly 30%. The market is now

IREN, NBIS, and CRWV: The Rise of Neoclouds in the AI Infrastructure Boom

Iris Energy (IREN), Nebius (NBIS) and Coreweave (CRWV) are frequently grouped due to their shared focus on AI infrastructure

Hedge Fund Tycoon Calls ‘Ten-Fold Opportunity,’ Fannie and Freddie Shares Both Surge Over 45%.

TradingKey - During Monday's U.S. Eastern trading session, shares of U.S. mortgage giants Fannie Mae and Freddie Mac experienced a rare surge, boosted by public bullish comments from renowned hedge fund manager Bill Ackman. Fannie Mae (FNMA) shares soared by more than 50%, while Freddie Mac (FMCC) jumped approximately 47%, becoming the focus of the market.

Bitcoin Price Analysis: What Is to Stop BTC from Making Another Run at All-Time Highs in 2026?

This strategic analysis covers institutional BTC price targets from JPMorgan and Fidelity, the impact of the U.S. Strategic Reserve, and whether the four-year cycle is broken. Stay updated on BTC to USD trends and key market risks.

Tesla (TSLA) 2026 Deep Dive Report: Behind the 5x Pricing Divergence, a Sunset Automaker or AI Giant?

An in-depth analysis of Tesla’s 2026 investment outlook, exploring the transformation into an AI giant and Robotaxi mass production plans behind Wall Street’s five-fold valuation gap. Through a comprehensive deconstruction of gross margin data, the energy business, and macro interest rate risks, we reveal the key investment signals and valuation reality for Tesla in 2026.

Tradingkey

KeyAI

